phone Contact Us

Program Pipeline

Opharmic Technology is advancing a focused pipeline of novel drug delivery and therapeutic solutions in ophthalmology and adjacent areas. Our proprietary ultrasound biomechanics platforms are progressing from comprehensive preclinical validation into clinical development, with first-in-human studies in preparation.

  Technology
Applied		 Development Phase Next Milestone
Ocular Drug Delivery
Novel IVT replacement
Ocular Drug Delivery
 Metictouch
Clinical Preparation
 FIH Study
Systemic Drug Delivery
Needle-free systemic delivery
 Metictouch
P.O.C.
 Preclinical Validation
Myopia
Myopia control and prevention
Myopia
 Meticstim
Preclinical
 Product Realization

 

Therapeutic Applications

Our preclinically validated programs are developed to address critical unmet needs across high-impact therapeutic areas

Technology 1

Ocular
Drug Delivery

Novel non-invasive ultrasound-enabled drug delivery platform for posterior segment eye diseases.

Technology 2

Myopia control
and prevention

Drug-free ultrasound stimulation platform for myopia control through precise modulation of scleral tissue biomechanics.

Technology 3

Systemic
Drug Delivery

Advanced skin penetration technology enabling systemic drug delivery through enhanced permeability.

Challenges

  • Over 300 million people worldwide are affected by AMD, DR, and DME1,2
  • Invasive injection as current standard of care
  • Low long-term treatment compliance
  • Heavy burden on healthcare infrastructure

Our Solution

  • Non-invasive & effective method
  • Patient & HCP Friendly
  • Compatibility with multiple drug products
  • Clear and de-risked regulatory and commercial pathway
Explore Platform

Challenges

  • Up to 80-90% Prevalence in East Asia3
  • 1 in 3 children with myopia globally4
  • Current available treatments shows variable efficacy and undesirable side effects
  • Low patient compliance

Our Solution

  • Non-pharmaceutical Approach
  • Mechanistically validated in preclinical models
  • Customizable parameters for tailored treatment protocols
  • Commercial Partnership Readiness
Learn More

Challenges

  • Invasive subcutaneous or intravenous injections
  • Inherent risk of injections
  • Patient discomfort and anxiety
  • Poor long-term compliance for repeated dosing

Our Solution

  • Needle-free, painless transdermal delivery
  • Enhanced patient compliance & comfort
  • Consistent bioavailability
  • Drug-agnostic technology
Learn More

Exploratory Programs

Dedicated resources support initial proof-of-concept and validation studies. Only concepts meeting rigorous technical, industrial, and commercial criteria advance to formal pipeline status. Current exploratory areas include:

Program 1

Cell-Based Therapy
Future-proof technology integration for advanced therapeutic modalities

Program 1

Topical Delivery
Next-generation transdermal solutions for localized treatment